Cognitive impairment in patients with metabolic syndrome. The current treatment possibilities

The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Search result: 0

Zueva I.B.

Saint-Petersburg medical-social Institute, Saint-Petersburg, Russia;
St. Petersburg clinical scientific and practical center for specialized types of medical care, Saint-Petersburg, Russia

Krivonosov D.S.

Saint-Petersburg medical-social Institute, Saint-Petersburg, Russia;
Almazov National medical research center, Saint-Petersburg, Russia

Buch A.V.

Almazov National medical research center, Saint-Petersburg, Russia

Kim Yu.V.

Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia

Cognitive impairment in patients with metabolic syndrome. The current treatment possibilities

Authors:

Zueva I.B., Krivonosov D.S., Buch A.V., Kim Yu.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(5): 18‑22

DOI: 10.17116/jnevro20181185118

Views: 875

Downloaded: 25

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zueva IB, Krivonosov DS, Buch AV, Kim YuV. Cognitive impairment in patients with metabolic syndrome. The current treatment possibilities. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(5):18‑22. (In Russ.)
https://doi.org/10.17116/jnevro20181185118

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)

Close metadata

Objective. To study the effect of therapy with cytoflavin on cognitive function in patients with metabolic syndrome (MS). Material and methods. The randomized controlled open study included 156 patients with MS. The mean age was 41.27±5.16 years. The duration of observation was 16 weeks. The main group of patients (n=78) received cytoflavin in the dose of 2 tablets 2 times a day. Patients in the control group (n=78) received basic therapy. All patients underwent neuropsychological testing at baseline, after 2 months and at the end of the study. Cognitive evoked potentials (Р300) were recorded to assess cognitive functions. The levels of plasma glucose and lipid profile were measured. Results. Cytoflavin improved cognitive functions. Two months after treatment, the results of neuropsychological testing and electrophysiological study were better in the main group compared to the control group.

Keywords:

metabolic syndrome

cognitive disorders

cytoflavin

Authors:

Zueva I.B.

Saint-Petersburg medical-social Institute, Saint-Petersburg, Russia;
St. Petersburg clinical scientific and practical center for specialized types of medical care, Saint-Petersburg, Russia

Krivonosov D.S.

Saint-Petersburg medical-social Institute, Saint-Petersburg, Russia;
Almazov National medical research center, Saint-Petersburg, Russia

Buch A.V.

Almazov National medical research center, Saint-Petersburg, Russia

Kim Yu.V.

Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia

List of references:

Brookmeyer R, Gray S. Methods for projecting the incidence and prevalence of chronic diseases in ageing populations: application to Alzheimer’s disease. Stat Med. 2000;19(11-12):1481-1493.
Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113-1132. https://doi.org/10.1016/j.jacc.2010.05.034
McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet. 2012;379:2291-2399. https://doi.org/10.1016/S0140-6736(12)60360-2
Gunstad J, Paul RH, Cohen RA, Tate DF, Spitznagel MB, Gordon E. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry. 2007;48:57-61. https://doi.org/10.1016/j.comppsych.2006.05.001
Dahl AK, Hassing LB, Fransson EI, Gatz M, Reynolds CA, Pedersen NL. Body mass index across midlife and cognitive change in late life. Int J Obes. 2013;37:296-302. https://doi.org/10.1038/ijo.2012.37
Novak V, Hajjar I. The relationship between blood pressure and cognitive function. Nat Rev Cardiol. 2010;7:686-698. https://doi.org/10.1038/nrcardio.2010.161
Koch M, Jensen MK. HDL-cholesterol and apolipoproteins in relation to dementia. Curr Opin Lipidol. 2016;27:76-87. https://doi.org/10.1097/MOL.0000000000000257
Zueva IB, Vanaeva KI, Sanez EL, Piotrovskaya VR, Genikhovich EL, Kirillova VI, Shlyakhto EV. Association of cognitive function with cardiovascular risk factors in middle age. J Hypertension. 2011;17(5):432-441.(In Russ.)
Efimova I, Efimova N, Lishmanov Y. Cerebral Blood Flow and Cognitive Function in Patients With Metabolic Syndrome: Effect of Antihypertensive Therapy. J Clin Hypertens (Greenwich). 2014;16(12):900-906. https://doi.org/10.1111/jch.12435
Sitburana O, Ondo WG. Brain magnetic resonance imagimg in parkinsonian disorders. Parkinsonism and Related Disorders. 2009;15:165-174. https://doi.org/10.1016/j.parkreldis.2008.04.033
Zueva IB, Moroshkina NV, Barantsevich ER, Trufanov GE. Magnetic resonance spectroscopy in evaluation of cognitive functions in patients with metabolic syndrome. J Hypertension. 2013;19(1):51-58. (In Russ.)
Bakker FC, Klijn CJ, Jennekens-Schinkel A, van der Tweel I, van der Grond J, van Huffelen AC, Tulleken CA, Kappelle LJ. Cognitive impairment is related to cerebral lactate in patients with carotid artery occlusion and ipsilateral transient ischemic attacks. Stroke. 2003;34(6):1419-1424. https://doi.org/10.1161/01.STR.0000069725.09499.14
Klijn CJM, Kappelle LJ, van der Grond J, Algra A, Tulleken CAF, van Gijn J. Magnetic resonance techniques for the identification of patients with symptomatic carotid artery occlusion at high risk of cerebral ischemic events. Stroke. 2000;31:3001-3007.
Belova LA, Mashin VV, Kolotik-Kamenev OYu, Belova NV, Angelo Scuderi, Pier Luigi Antignani. Effect of cytoflavin on the clinical and autonomic-psychological manifestations of hypertensive disease. Therapeutic archive. 2016;88(5):55-61. (In Russ.) https://doi.org/10.17116/terarkh201688555-61
Muratov FH, Shermuhamedova FK, Batotsyrenov BV, Kharitonova TV. Multimodal action of cytoflavin in acute cerebral stroke, developed on the background of metabolic syndrome. Journal of neurology and psychiatry im. S.S. Korsakov. 2016;116(12):44-47. (In Russ.) https://doi.org/10.17116/jnevro201611612144-47

Close metadata

Log in to the site using your account in one of the services

Registration

Last Name

Name

Middle Name

E-mail

Phone

Address

Country

Zip

City

Region

Street

Home

Apartmen

Legal entity name

ИНН

КПП

Password

Password

Repeat password

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.